ANTX AN2 Therapeutics, Inc.

89

Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]

US | NASDAQ | Stock

Price
$15.47
Decreased by -0.83%
Dollar Volume
193.90 K
ADR%
8.06
Market Cap.
300.16 M
Shares Float
5.59 M
Shares Outstanding
19.40 M
Beta
0.00
Price / Earnings
-1.24
BPR
228.89
20D Range
9.15 16.00
50D Range
8.30 16.00
200D Range
6.88 23.58
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.59 -0.59
Aug 11, 22 -0.53 -0.46
Decreased by -15.22%
May 10, 22 -2.98 -0.52
Decreased by -473.08%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
 -11.34 M
Decreased by -126.46%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -10.12 M
Decreased by -394.14%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00 - -7.66 M -
Decreased by N/A%
-
Sep 30, 21 0.00 - -6.94 M -
Decreased by N/A%
-
Jun 30, 21 0.00 - -5.01 M -
Decreased by N/A%
-
Mar 31, 21 0.00 - -2.05 M -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.